Attached files
| file | filename |
|---|---|
| 10-Q/A - FORM 10-Q/A - Orexigen Therapeutics, Inc. | d114769d10qa.htm |
| EX-31.1 - EX-31.1 - Orexigen Therapeutics, Inc. | d114769dex311.htm |
| EX-10.1 - EX-10.1 - Orexigen Therapeutics, Inc. | d114769dex101.htm |
| EX-31.2 - EX-31.2 - Orexigen Therapeutics, Inc. | d114769dex312.htm |
| EX-32.2 - EX-32.2 - Orexigen Therapeutics, Inc. | d114769dex322.htm |
Exhibit 32.1
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Amendment No. 1 on Form 10-Q/A of Orexigen Therapeutics, Inc. (the “Company”), for the period ending September 30, 2015 (the “Report”), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: January 12, 2016
| /s/ Michael A. Narachi |
| Michael A. Narachi President and Chief Executive Officer |
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.